Progress in the identification of gene mutations involved in multiple myeloma
Authors:
Open Access
- 1 May 2019
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 4075-4080
Abstract
Sequencing studies have been used to determine a spectrum of multiple myeloma (MM) mutations. Mutation of certain genes, including KRAS, NRAS, TP53, FAM46C, DIS3 and BRAF, have a high recurrence rate and may play important roles in the pathogenesis, progression and prognosis of MM. Mutations in DIS3, which encodes a highly conserved RNA exonuclease, lead to loss of function. The expression of FAM46C is highly correlated with the expression of ribosomal protein, but the exact function of FAM46C mutation is unclear. There are mutants of IRF4, which is considered an MM survival factor. Mutations in the gene coding for the DNA damage-binding protein (DDB1) may affect interactions with CUL4A, which is part of the cereblon (CRBN) ubiquitin ligase complex. IRF4is part of the complex, which binds to DNA. These findings might explain the resistance to immunomodulatory. TP53 deletion or mutation is often present in B-cell malignancies and is associated with low response rates. Myeloma pathogenic mutations in ATM have been found in adult lymphatic tumors. XBP1 and PSMB5 mutations may be related to bortezomib resistance. Multiple gene mutations (KRAS, NRAS and BRAF) involved in the same pathway were found a single patient. Identification of driver gene mutations has brought great hope to the field of individualized, targeted medicine for MM.Keywords
This publication has 36 references indexed in Scilit:
- Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling moleculesBlood Cancer Journal, 2013
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Blood, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- Classical and/or alternative NF-κB pathway activation in multiple myelomaBlood, 2010
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivoBritish Journal of Haematology, 2010
- Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myelomaBlood, 2010
- IRF4 addiction in multiple myelomaNature, 2008
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- A single subunit, Dis3, is essentially responsible for yeast exosome core activityNature Structural & Molecular Biology, 2006
- Conservation and evolvability in regulatory networks: The evolution of ribosomal regulation in yeastProceedings of the National Academy of Sciences, 2005